[go: up one dir, main page]

EP4232045A4 - BERBERINE URSODEOXYCHOLATE COMPOSITIONS AND METHODS THEREOF FOR THE TREATMENT OF FATTY LIVER DISEASE, DIABETES AND HYPERLIPIDEMIA - Google Patents

BERBERINE URSODEOXYCHOLATE COMPOSITIONS AND METHODS THEREOF FOR THE TREATMENT OF FATTY LIVER DISEASE, DIABETES AND HYPERLIPIDEMIA Download PDF

Info

Publication number
EP4232045A4
EP4232045A4 EP21882127.0A EP21882127A EP4232045A4 EP 4232045 A4 EP4232045 A4 EP 4232045A4 EP 21882127 A EP21882127 A EP 21882127A EP 4232045 A4 EP4232045 A4 EP 4232045A4
Authority
EP
European Patent Office
Prior art keywords
hyperlipidemia
diabetes
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21882127.0A
Other languages
German (de)
French (fr)
Other versions
EP4232045A1 (en
Inventor
Liping Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Hightide Biopharmaceutical Ltd
Original Assignee
Shenzhen Hightide Biopharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Hightide Biopharmaceutical Ltd filed Critical Shenzhen Hightide Biopharmaceutical Ltd
Publication of EP4232045A1 publication Critical patent/EP4232045A1/en
Publication of EP4232045A4 publication Critical patent/EP4232045A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21882127.0A 2020-10-23 2021-10-22 BERBERINE URSODEOXYCHOLATE COMPOSITIONS AND METHODS THEREOF FOR THE TREATMENT OF FATTY LIVER DISEASE, DIABETES AND HYPERLIPIDEMIA Pending EP4232045A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063104754P 2020-10-23 2020-10-23
PCT/CN2021/125490 WO2022083713A1 (en) 2020-10-23 2021-10-22 Compositions of berberine ursodeoxycholate and methods thereof for treating fatty liver disease, diabetes and hyperlipidemia

Publications (2)

Publication Number Publication Date
EP4232045A1 EP4232045A1 (en) 2023-08-30
EP4232045A4 true EP4232045A4 (en) 2024-09-04

Family

ID=81289703

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21882127.0A Pending EP4232045A4 (en) 2020-10-23 2021-10-22 BERBERINE URSODEOXYCHOLATE COMPOSITIONS AND METHODS THEREOF FOR THE TREATMENT OF FATTY LIVER DISEASE, DIABETES AND HYPERLIPIDEMIA

Country Status (3)

Country Link
EP (1) EP4232045A4 (en)
CN (1) CN116782898A (en)
WO (1) WO2022083713A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023088463A1 (en) * 2021-11-22 2023-05-25 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods of berberine ursodeoxycholate for modulating gut microbiome compositions
WO2024120452A1 (en) * 2022-12-07 2024-06-13 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods for prophylaxis and treatment of covid-19
EP4665727A1 (en) * 2023-02-15 2025-12-24 Shenzhen Hightide Biopharmaceutical Ltd. Berberine tauroursodeoxycholate compositions and methods thereof
WO2024179570A1 (en) * 2023-03-01 2024-09-06 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods for treating severe hypertriglyceridemia
WO2025130826A1 (en) * 2023-12-18 2025-06-26 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Compositions and methods for treating cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009011420A1 (en) * 2007-07-18 2009-01-22 Mitsubishi Tanabe Pharma Corporation Therapeutic agent for type-2 diabetes
WO2010106420A1 (en) * 2009-03-17 2010-09-23 Axcan Pharma, Inc. Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid
WO2016015634A1 (en) * 2014-07-29 2016-02-04 Shenzhen Hightide Biopharmaceutical, Ltd. Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108864077B (en) * 2017-05-12 2020-05-22 深圳君圣泰生物技术有限公司 Solid form of berberine organic acid salt and preparation method thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009011420A1 (en) * 2007-07-18 2009-01-22 Mitsubishi Tanabe Pharma Corporation Therapeutic agent for type-2 diabetes
WO2010106420A1 (en) * 2009-03-17 2010-09-23 Axcan Pharma, Inc. Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid
WO2016015634A1 (en) * 2014-07-29 2016-02-04 Shenzhen Hightide Biopharmaceutical, Ltd. Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
LI ZHAO ET AL: "Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease", BMC ENDOCRINE DISORDERS, BIOMED CENTRAL LTD, LONDON, UK, vol. 17, no. 1, 28 February 2017 (2017-02-28), pages 1 - 8, XP021242660, DOI: 10.1186/S12902-017-0165-7 *
LIU L ET AL: "HTD1801 a novel treatment addressing the underlying metabolic features of NAFLD/NASH", HEPATOLOGY V70 SUPPL.1 2019 20191001 JOHN WILEY AND SONS INC. NLD, vol. 70, no. Supplement 1, 1 October 2019 (2019-10-01), XP009555841, ISSN: 1527-3350 *
LIU, LP; BAI, R; YU, L; YU, M; FU, XX: "HTD1801 A NOVEL TREATMENT FOR NAFLD/NASH AND PRIMARY SCLEROSING CHOLANGITIS (PSC)", HEPATOLOGY, vol. 70, no. Suppl 1, 1 October 2019 (2019-10-01), pages 1261A - 1262A, XP009555813 *
See also references of WO2022083713A1 *
XING LIAN-JUN ET AL: "Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 668, no. 3, 1 October 2011 (2011-10-01), NL, pages 467 - 471, XP093189113, ISSN: 0014-2999, DOI: 10.1016/j.ejphar.2011.07.036 *
ZHANG HAO ET AL: "Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression", METABOLISM, vol. 59, no. 2, 1 February 2010 (2010-02-01), US, pages 285 - 292, XP093189125, ISSN: 0026-0495, DOI: 10.1016/j.metabol.2009.07.029 *

Also Published As

Publication number Publication date
WO2022083713A1 (en) 2022-04-28
CN116782898A (en) 2023-09-19
EP4232045A1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
EP4232045A4 (en) BERBERINE URSODEOXYCHOLATE COMPOSITIONS AND METHODS THEREOF FOR THE TREATMENT OF FATTY LIVER DISEASE, DIABETES AND HYPERLIPIDEMIA
EP4281464A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES
EP4373939A4 (en) GENOMEDITATION COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC GRANULOMATOSIC DISEASE
EP3973047A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF LIVER DISEASES
EP3826666A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NRP2-ASSOCIATED DISEASES
DE602006018583D1 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF PERIPHERAL VASCULAR DISEASES
EP1881823A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF EYE DISEASES
EP3969597A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATPASE-MEDIATED DISEASES
EP4415755A4 (en) ACE2-TARGETED COMPOSITIONS AND METHODS FOR THE TREATMENT OF COVID-19
EP4204443A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLIOBLASTOMA
EP4384219A4 (en) COMPOSITIONS, DOSES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
EP3740592A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF VASCULAR DISEASES
EP3986439A4 (en) COMPOSITIONS AND METHODS FOR TREATING BRAIN DISEASES
EP4401745A4 (en) Methods and uses of microbiome compositions, components, or metabolites for the treatment of neurodegenerative diseases
EP4045094A4 (en) COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASE
EP3781158A4 (en) COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC FAT LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS
EP3976053A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF METABOLIC DISEASES
EP3990018A4 (en) METHODS AND COMPOSITIONS FOR TREATING ALZHEIMER'S DISEASE
EP4340860A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROPATHY
EP4188346A4 (en) NOBILETIN COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF COVID-19 AND RELATED DISEASES
EP4034109A4 (en) METHOD AND COMPOSITION FOR TREATING DISEASES
EP4025199A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2142566A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP4340835A4 (en) Methods and compositions for the treatment of cardiovascular diseases
EP4340897A4 (en) Methods and compositions for the treatment of pancreatic and liver diseases

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230517

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240806

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/48 20060101ALI20240731BHEP

Ipc: A61K 9/20 20060101ALI20240731BHEP

Ipc: A61P 3/10 20060101ALI20240731BHEP

Ipc: A61P 3/06 20060101ALI20240731BHEP

Ipc: A61P 1/16 20060101ALI20240731BHEP

Ipc: A61K 31/4375 20060101ALI20240731BHEP

Ipc: A61K 31/575 20060101AFI20240731BHEP